Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Intensity Chemotherapy for Burkitt Lymphoma and L3 ALL
NCT00002494Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 1992
- Primary completion
- Mar 2004
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, ifosfamide, methotrexate, vincristine, cytarabine and 4 more in Burkitt lymphoma (BL) and Burkitt leukemia, sponsored by Cancer and Leukemia Group B. Primary endpoints: Response Rate and Disease Free Survival. Started May 1992; status: completed.
02
Drugs
cyclophosphamideifosfamidemethotrexatevincristinecytarabine
03
Conditions
Burkitt lymphoma (BL)Burkitt leukemia
Beyond the preview
Go deeper on NCT00002494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002494.